Curis Inc. (NASDAQ: CRIS) has expanded its executive leadership with the addition of Felix Geissler as VP of Medical Affairs, Dora Ferrari as VP Clinical Operations, and Kimberly Steinmann as VP Clinical Development. The new appointees will report directly to SVP Clinical Development, Reinhard von Roemeling.
Curis makes three executive appointments.
CEO James Dentzer said, “We are pleased to welcome Felix, Kim and Dora to our management team. They are outstanding professionals in the industry and bring expertise that we believe will strengthen our internal capabilities as we look to advance the development of our clinical drug candidates, CA-4948 and CI-8993. We look forward to their contributions as we strive to achieve our mission to develop innovative and differentiated therapeutics that improve the lives of cancer patients.”
Geissler has over two decades of experience in designing and directing strategic operations as well as healthcare management activities. He is a certified immunologist and board-certified surgeon with massive experience in clinical research and medical affairs. Previously he was working at Horizon therapeutics as VP Medical Affairs, where he was in charge of medical Affairs strategy development and directing operations for the company’s marketed portfolio.
Steinmann, on the other hand, also has over twenty years of experience as a certified pediatric oncologist/hematologist and pediatric emergency medicine physician, she has worked at Takeda as a consultant to the company’s oncology development program. Before Takeda, she worked as an Orphan Diseases Executive Medical Director at Grifols.
Ferrari has experience in the biotech sector
Ferrari is an expert in end-to-end drug development with two decades of biotech sector experience. She previously led clinical operations and program management at Aileron Therapeutics as VP of Clinical Development and Program Management. Notably, she worked at ArQule in various positions. Ferrari was in charge of managing programs from pre-IND to all levels of clinical development at ArQule. Equally, she oversaw the development team for ArQule’s BTK project from IND approval to early-stage clinical operations, culminating in Merck’s acquisition of ArQule. In addition, Ferrari worked previously at Ziopharm Oncology and Epix Pharmaceuticals, where she was a member of the team that helped Vasovist gain FDA approval.
